Bisphosphonates, bone, and breast cancer recurrence

The Lancet

Volumn 386, Issue 10001, 2015, Pages 1319-1320

  Brufsky, Adam ^a   Mathew, Aju ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

BONE CANCER; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; DISEASE FREE SURVIVAL; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; NOTE; OSTEOCLAST ACTIVITY; POSTMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; BREAST NEOPLASMS; FEMALE;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 84944172496     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61163-1     Document Type: Note

References (14)

1. M Favus Bisphosphonates for osteoporosis N Engl J Med 363 2010 2027 2035
2. CH Van Poznak, S Temin, GC Yee et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer J Clin Oncol 29 2011 1221 1227
3. A Brufsky, WG Harker, JT Beck et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer J Clin Oncol 25 2007 829 836
4. S Paget The distribution of secondary growths in cancer of the breast Lancet 133 1889 571 573
5. G Roodman Mechanisms of bone metastasis N Engl J Med 350 2004 1655 1664
6. T Powles, A Paterson, E McCloskey et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] Breast Cancer Res 8 2006 R13
7. T Saarto, C Blomqvist, P Virkkunen, I Elomaa Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 19 2001 10 17
8. R Coleman, R De Boer, H Eidtmann et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results Ann Oncol 24 2013 398 405
9. M Gnant, B Mlineritsch, H Stoeger et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Lancet Oncol 12 2011 631 641
10. RE Coleman, H Marshall, D Cameron et al. Breast-cancer adjuvant therapy with zoledronic acid N Engl J Med 365 2011 1396 1405
11. Early Breast Cancer Trialists' Collaborative Group Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Lancet 2015 published online July 24. http://dx.doi.org/10.1016/S0140-6736(15)60908-4
12. Early Breast Cancer Trialists' Collaborative Group Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Lancet 379 2012 432 444
13. TR Cox, RMH Rumney, EM Schoof et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase Nature 522 2015 106 110
14. M Gnant, G Pfeiler, PC Dubsky et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial Lancet 2015 published online May 31. http://dx.doi.org/10.1016/S0140-6736(15)60995-3